Furthermore, our data showed that DDR1 inhibitors suppressed progression and angiogenesis in patient‐derived xenograft (PDX) and organoid models, highlighting the translational value of targeting the DDR1‐HIF1α axis for treating GC. This evidence concerns the gene DDR1 and gastric cancer.